

Drug and Therapeutics Committee – Minutes –Confirmed

Date / Time	Thursday 11 th May 2017
Venue	The Board Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG)
Quorate: Yes / No	Yes

Attendance	Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG) Dr H Klonin, Consultant Paediatrician Mr K McCorry, Medicines Management, East Riding Dr O Ogunbambi, Consultant Rheumatologist Prof M Lind, Vice Chair, Professor of Oncology Dr F Umerah, Consultant Anaesthetist Miss J Morgan, Senior Principal Pharmacist – Interface – deputy for D Corral & P O'Brien
-------------------	---

Apologies	Mr P O'Brien, Deputy Chief Pharmacist Dr A Samson, Infectious Diseases Consultant Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr Roper, Chair, Hull CCG Mr R Kapur, Vascular Surgeon Dr S Raise, GP Prescribing Lead, ER Mrs Sue Phillips, Lay Representative
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.05.01	Apologies	As Above.					
2017.05.02	Declarations of Interest	None.					
2017.05.03	Minutes of the previous meeting	The minutes were accepted as a true record.					5/17
2017.05.04	Action Tracker	<p>Alteplase (Actilyse Cathflo) AM had written to applicant.</p> <p>Epclusa (Sofosbuvir and Velpatasvir) SG had updated the formulary.</p> <p>Stalevo and Generics SG had added to MMIG Agenda.</p> <p>NICE TA 439 Panitumumab ML had asked for a new product request</p> <p>NICE TA340 Ustekinumab SG had updated the formulary.</p> <p>MHRA DSU SPG had asked MM to discuss at Medicine HG Governance Meeting.</p> <p>Clinical Guideline for Phenytoin Loading and Maintenance Doses DC had arranged for SPG to attend the Trust intranet committee meeting on 11/05/17 and Myles Howell had been invited to attend D&TC, hopefully in June/17.</p> <p>Soolantra Correspondence AM had written to Dr Zaman and SG had added to HERPC Agenda</p>	<p>Action Complete.</p>				<p>5/17</p> <p>5/17</p> <p>5/17</p> <p>5/17</p> <p>5/17</p> <p>5/17</p> <p>5/17</p>

		<p>Fluticasone furoate and Vilanterol (Relvar Ellipta) POB to discuss and clarify commissioning DOT with respiratory service manager – still waiting to hear.</p> <p>AM had discussed with Severe Asthma Team, who would prefer to use Relvar. AM pointed out that the licence and supporting papers show that Symbicort can be used daily and as “SMART” and could be used following the DOT period.</p> <p>Stalevo and Generics AM had written to Dr Ming to thank him for his input.</p> <p>Update: KM asked AM to send a copy of the correspondence with Dr Ming.</p> <p>Bisphosphonates as Supportive Therapy for Breast Cancer – ML to write local protocol then send to SG for discussion at HERPC Dr Dhadda is preparing.</p> <p>Minutes from HERPC – 25/01/17 - Paediatric Growth Hormone SG had added to HERPC agenda for further discussion.</p>	<p>Commissioning requires clarification. Relvar should be used for DOT then patients could switch to Symbicort</p> <p>Action Complete</p> <p>AM to send copy to KM</p> <p>Ongoing</p> <p>Action Complete</p>	<p>POB to ask service manager</p> <p>To go to HERPC for discussion of status</p> <p>Ongoing</p>	<p>POB</p> <p>SG</p> <p>AM</p> <p>ML</p>	<p>6/17</p> <p>6/17</p> <p>6/17</p> <p>05/17</p>	<p>5/17</p> <p>5/17</p>
2017.05.05	New Product Requests	<p>Daclizumab (Zinbryta) SC Pre-filled Injection - Dr James Harley Approved in line with NICE TA441</p> <p>Brivaracetam (Briviact)- Dr A Ming There were concerns about how patients would be initiated, monitored and followed up to assess for effectiveness. AM would write to Dr Ming to clarify his planned arrangements.</p> <p>Obeticholic Acid (Ocaliva) Capsules- Dr Lynsey Corless Approved in line with NICE TA443. It was thought this would be PbR excluded & commissioned by NHS under a PAS scheme.</p>	<p>Approved.</p> <p>Approved, with arrangements to be clarified.</p> <p>Approved.</p>	<p>AM to write to applicants</p> <p>AM to write to Dr Ming</p> <p>JM to clarify commissioning arrangements with POB</p>	<p>AM</p> <p>AM</p> <p>JM/POB</p>	<p>6/17</p> <p>6/17</p> <p>6/17</p>	

2017.05.06	NICE Guidance - April 2017	<p>NICE Guidance April 2017</p> <p>Sexually transmitted infections: condom distribution schemes https://www.nice.org.uk/guidance/ng68</p> <p>Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine after gemcitabine https://www.nice.org.uk/guidance/ta440</p> <p>Daclizumab for treating relapsing–remitting multiple sclerosis https://www.nice.org.uk/guidance/ta441</p> <p>Ixekizumab for treating moderate to severe plaque psoriasis https://www.nice.org.uk/guidance/ta442</p> <p>Obeticholic acid for treating primary biliary cholangitis https://www.nice.org.uk/guidance/ta443</p> <p>Alcohol-use disorders: diagnosis and management of physical complications https://www.nice.org.uk/guidance/cg100</p> <p>Irritable bowel syndrome in adults: diagnosis and management https://www.nice.org.uk/guidance/cg61</p>	<p>Noted, not about drugs.</p> <p>Non-formulary, negative appraisal.</p> <p>Approved as above.</p> <p>Non-formulary, application needed.</p> <p>Approved as above.</p> <p>Noted, steroids are on formulary.</p> <p>Noted, not about drugs.</p>	<p>No further action</p> <p>No further action</p> <p>No further action</p> <p>AM to write to Dr Zaman</p> <p>No further action</p> <p>No further action</p> <p>No further action</p>	<p></p> <p></p> <p></p> <p>AM</p> <p></p> <p></p>	<p></p> <p></p> <p></p> <p>6/17</p> <p></p> <p></p>	<p>5/17</p> <p>5/17</p> <p>5/17</p> <p></p> <p>5/17</p> <p>5/17</p>
2017.05.07	MHRA DSU – April 2017	<p>Valproate and neurodevelopmental disorders: new alert asking for patient review and further consideration of risk minimisation measures Dr Klonin confirmed that W&C HG was aware of this and had also received the national Patient Safety Alert letter. The alert is being progressed at SMPC, with Paediatrics & Neurology having discussions about the actions required. To be discussed at HERPC also, regarding response to alert in community.</p> <p>Ponatinib (Iclusig ▼): risk of vascular occlusive events— updated advice on possible dose reduction</p> <p>Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy JM informed the group that she will update Neurology on this.</p>	<p>Noted. To be discussed at HERPC.</p> <p>Haematology to be informed</p> <p>Noted.</p>	<p>Add to May HERPC agenda</p> <p>AM to write to Dr S Ali</p>	<p>SG</p> <p>AM</p>	<p>6/17</p> <p>6/17</p>	<p></p> <p></p> <p>5/17</p>

2017.05.08	Minutes from SMPC	None					
2017.05.09	Unconfirmed Minutes from HERPC – 22/03/17	Noted. Fluticasone furoate and Vilanterol (Relvar Ellipta) - Should be RED status, as only approved by D&TC for DOT. Dr Smith - to be changed to Mr Smith.	Unconfirmed minutes to be amended.	SG to amend minutes	SG	6/17	
2017.05.10	Correspondence Received	<p>Dr Hammersley – dexamphetamine This GP had written to Prof Morice regarding a patient with severe post-traumatic stress disorder, following an assault in 1997. He had been prescribed dexamphetamine to help with his libido and erectile dysfunction by his Psychiatrist – Dr Merolli, who has since retired. Dr Ma, his new psychiatrist, had written to Dr Hammersley to say that in spirit he would endorse the continuation of the drug to help boost his sexual confidence, but that he felt unable to prescribe for this unlicensed indication. Dr Joshi has written to Dr Hammersley, stating that he had prescribed testosterone replacement therapy to the patient, but would not prescribe dexamphetamine for this indication for any patient. Dr Hammersley asked Prof Morice for authorisation to be able to prescribe dexamphetamine for his patient and to provide a shared care framework to support his prescribing. KM stated that this issue was raised at Humber FT D&T for approval and was declined. Prof Morice had already written to Dr Hammersley stating that he is the chair of HEY D&T Committee, but that our remit does not cover psychiatric services (under Humber FT) or Genitourinary Medicine/Sexual Health Services (under CHCP). Therefore he was unable to authorise this prescribing, but would agenda the correspondence for discussion to see if anyone had any bright ideas about how to progress the matter. The Committee agreed that this was not a matter for HEY D&TC, but would refer the issue to HERPC for discussion.</p> <p>Dr Gowda – Cantharone & Cantharone plus When this product as considered at D&TC a question was raised about the lower age limit for use in children. A letter has been received from Dr Gowda that it would be used in children over 5 years old.</p>	<p>This was not a matter for HEY D&T. Refer to HERPC for discussion.</p> <p>This was thought to be satisfactory.</p>	<p>SG to agenda at HERPC and circulate the letters received.</p> <p>No further action</p>	SG	6/17	5/17

2017.05.11	Chairs Approvals	Campath (Alemtuzumab) - Dr T Jorna Kidney transplant recipient - steroid resistant rejection of transplant	Noted	No further action			5/17
2017.05.12	Issues to Escalate to Operational Quality Committee	None					5/17
2017.05.13	Any Other Business	None					5/17
2017.05.15	Date and Time of Next Meeting	Date – Thursday 8th June 2017 Time – 8.15am-9.30am Venue – Board Room, Alderson House, HRI					